Exelixis, Inc. (EXEL)

NMS – Real Time Price. Currency in USD

49.46

-0.25 (-0.50%)

At close: May 12, 2026, 4:00 PM EDT

49.46

0.00 (0.00%)

Pre-market: May 13, 2026, 4:11 AM EDT

07.05.2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026: Exelixis is scheduled to present at 1:00 p.m. ET / 10:00 a.m. PT on Tuesday, May 12 in Las Vegas. 2026 RBC Capital Markets Global Healthcare Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, May 19 in New York City. 2026 Stifel Vir.

06.05.2026

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.

06.05.2026

Here's Why Exelixis (EXEL) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

06.05.2026

Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript

05.05.2026

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

05.05.2026

Exelixis (EXEL) Tops Q1 Earnings Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.62 per share a year ago.

05.05.2026

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis made significant progress in the first quarter of 2026 as we remain focused on our goal of building next-generation oncology franchises,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, E.

Videos

No Data

There is no data to display

Press releases

05.05.2026

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

10.02.2026

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis delivered strong results in 2025 and is well positioned for a breakout year in 2026,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “The cabozantinib franchis.

02.02.2026

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. The Food and D.

11.01.2026

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier.

Exelixis, Inc. (EXEL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Exelixis, Inc. (EXEL)

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Here's Why Exelixis (EXEL) is a Strong Value Stock

Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Tops Q1 Earnings Estimates

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Here's Why Exelixis (EXEL) is a Strong Value Stock

Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Tops Q1 Earnings Estimates

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Search stocks

Exelixis, Inc. (EXEL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Exelixis, Inc. (EXEL)

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Here's Why Exelixis (EXEL) is a Strong Value Stock

Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Tops Q1 Earnings Estimates

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Here's Why Exelixis (EXEL) is a Strong Value Stock

Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Tops Q1 Earnings Estimates

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026